Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05070299
Other study ID # UMCC 2021.071
Secondary ID HUM00202063
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2022
Est. completion date August 29, 2022

Study information

Verified date February 2023
Source University of Michigan Rogel Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm study to evaluate the feasibility, adherence, and usefulness of a psychosexual education partner program (PEPP) to improve partner communication and sexual function. This study is intended to get initial input from a small group of up to 10 women and their partners about the appropriateness, usefulness, and critical nature of the content as well as the feasibility and appeal of the method of delivery.


Description:

The overall objective of this program of research is to improve sexual health outcomes for women diagnosed with breast or gynecologic cancer. The investigators are developing a multi-component intervention for the four key predictors of sexual health in female cancer survivors: self-image, vaginal symptoms, desire/energy, and relationship-partner concerns. This proposal addresses the evaluation of this last component, relationship-partner concerns. The planned intervention to address these concerns is a psychosexual education partner program (PEPP) delivered by workbook and three follow up phone calls (to coincide with the end of each module) to women and their partners who have experienced a negative change in their relationship since their cancer diagnosis. Ten women with breast or gynecological cancer and their stable partners (ten dyads) will evaluate the content and delivery method of the intervention through self-report questionnaires and a qualitative interview.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 29, 2022
Est. primary completion date August 29, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Eligibility Criteria below apply only to the patient. (The patient's partner must be 18 years of age or older.) Patient Inclusion Criteria: 1. Age =18 female with a history of any stage breast and/or gynecological cancer. 2. Completed primary treatment (chemotherapy, radiation and/or surgery) = 3 months and = 5 years prior to registration. 3. May use concurrent adjuvant endocrine therapy or HER2-targeted therapy while on study. 4. Responds yes to the question "Has there been change in communication and/or intimacy with your partner since your cancer diagnosis?" 5. Ability to read and write English. 6. A stable partner, defined as anyone with whom the woman has had an intimate relationship with for at least 3 months prior to her cancer diagnosis. 7. Both partner and woman must agree to participate in the study and sign informed consent to the study. Patient Exclusion Criteria: 1. Antidepressants are allowed if a person has been on them for 30 days prior to registration, and dose or treatment is not expected to change. 2. Past history of sexual abuse. 3. Psychiatric disorder such as major depressive disorder, bipolar disorder, obsessive compulsive disorder or schizophrenia. (Defined per medical history and/or patient self-report.) 4. Currently enrolled in another study that addresses sexual health (enrollment in other clinical trials will be allowed).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Psychosexual Educational Partner Program (PEPP)
A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.

Locations

Country Name City State
United States University of Michigan Rogel Cancer Center Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Rogel Cancer Center The Breast Cancer Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attrition rate (feasibility) After completion of each module the interventionist will contact patients and their partners by phone and document completion of the module's exercise. Anyone who does not provide data both before and after completing the surveys for the study will be considered to be prematurely withdrawn and included in the attrition count. The intervention will be considered feasible if the attrition rate is 25% or less at week 6 (+2 weeks). Withdrawal reasons will be captured and reported by category. Week 6 (+2 weeks)
Secondary Home practice rate (acceptability) At each follow up phone call the interventionist will document participant progress and completion of the module's exercise. This documentation will include an assessment of whether or not both participants reviewed the module (yes/no), if no who did not review content, completion of module activities (yes/no), if no which activity was not completed. This documentation will be used to calculate adherence rates by dyad and individual. Week 6 (+2 weeks)
Secondary Participant experience assessed using Thematic Analysis Participant experience will be evaluated using the investigator-developed interview guide, which asks questions to assess usefulness, timing, delivery, content and perceived benefit. Research staff will record (either via audio or HIPAA-compliant video platform) participant responses to participant experience questions. Responses will be transcribed and then reviewed by two study team members and discussed in detail. Data analysis will be grounded in the theory of Thematic Analysis, which has been proven to be an effective framework for uncovering meaning in qualitative data. The research team will then connect the codes to try to identify themes for participant experience. Week 6 (+2 weeks)
Secondary Impact of intervention, measured by Dyadic Sexual Communication (DSC) DSC is a single dimensional 13-item scale that measures sexual communication between partners on a Likert scale, 1-disagree strongly to 6- agree strongly. Data will be summarized using descriptive statistics. To measure the effect size, Cohen's d or f, will be calculated for from baseline to week 6. Baseline to week 6 (+2 weeks)
Secondary Impact of intervention, measured by PROMIS® Sexual Function and Satisfaction V2.0 (PROMIS SexF V2) PROMIS SexF V2 measures sexual activities, symptoms, functioning, and evaluation of sexual experiences. General screener items ask about sexual activity and reasons for not having sexual activity in the past 30 days. Researchers are encouraged to select the sexual function and satisfaction domains and items that are relevant to the specific sample being studied. For this study, this measure will be administered to both partners. Females will answer the 14 item version and males will answer a 10 item version. In this instrument, higher scores indicate more of the thing being described by the domain. Effect sizes will be calculated from baseline to week 6. Data will be summarized using descriptive statistics. To measure the effect size, Cohen's d or f, will be calculated for from baseline to week 6. Baseline to week 6 (+2 weeks)
Secondary Impact of intervention, measured by Revised Dyadic Adjustment Scale (RDAS) RDAS is a 14-item scale with 3 themes (satisfaction, cohesion, and consensus) that measures an individual's perception of the quality of relationship with an intimate partner using a 6 point Likert scale; score range from 0 to 69. Higher scores indicate more positive dyadic adjustment. Scores of 47 and below indicate relationship distress. Data will be summarized using descriptive statistics. To measure the effect size, Cohen's d or f, will be calculated for from baseline to week 6. Baseline to week 6 (+2 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A